Original Articles Open Access
Copyright ©The Author(s) 2000. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Oct 15, 2000; 6(5): 693-698
Published online Oct 15, 2000. doi: 10.3748/wjg.v6.i5.693
Expressions of chromogranin A and cathepsin D in human primary hepatocellular carcinoma
Xiao Feng Huang, Chun Mei Wang, Department of Electron Microscopy, Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China
Xiao Wen Dai, Zhen Jiang Li, Li Bin Yu, Bin Qian, Li Fang, Department of Pathology, Chinese PLA 117 Hospital, Hangzhou 310013, Zhejiang Province, China
Bo Rong Pan, Room 12, Building 621, Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China
Xiao Feng Huang, earned Ph.D from the Fourth Military Medical University in 1997, now working in the Department of Electron Microscopy, Fourth Military Medical University, having 52 papers published.
Author contributions: All authors contributed equally to the work.
Supported by the Foundation of Chinese PLA 117 Hospital, No.98009
Correspondence to: Xiao Feng Huang, Department of Electron Microscopy, Fourth Military Medical University, Xi’an 710032, Shaanxi Province, China. fmmuem@fmmu.edu.cn
Telephone: 0086-29-3374572
Received: May 6, 2000
Revised: May 25, 2000
Accepted: June 2, 2000
Published online: October 15, 2000

Abstract

AIM: To determine the expression and clinical significance of chromogranin A and cathepsin D in hepatocellular carcinoma (HCC).

METHODS: Double immunofluorescence staining techniques combined with laser confocal scanning microscopy (LSCM) was used to investigate chromogranin A and cathepsin D expressions in 85 HCC patients.

RESULTS: Cathepsin D was expressed in 3 normal liver tissues, while in HCC the staining showed regional variation and the fraction of strongly stained cells increased as the tumors became less differentiated and usually clinically more malignant. Cells which showed strong positivity for cathepsin D were present in 71/85 (83.5%) cases. Strong expression of cathepsin D in cancer cells was related to histopathological features. They were more common in grade 3-4 (26/28, 92.9%) and grade 2 (46/53, 86.8%) tumors than in grade 1 tumors (1/4, 25.0%) (P < 0.01). No significant correlation was found between age and cathepsin D expression. In patients with positive cathepsin D reaction, the mean age was 52.1 ± 2.8 years (range 32-68 years) and in the group with negative reaction, the mean age was 51.3 ± 4.5 years (range 28-71 years). No obvious relationship was observed between CgA expression in cancer cells and the histopathological features. The CgA positive rate was 75.0% (3/4) in grade 1, 71.7% (38/53) in grade 2, and 71.4% (20/28) in grade 3-4 (P > 0.05) tumors. The coexpression of CgA and cathepsin D was found by double labeled immunofluorescence staining techniques. The processing of cathepsin D was disturbed in HCC cells and accumulated in the cells. Cathepsin D had proteolytic activity and autocrine mitogenic effect, suggesting their functions in invasion. These findings demonst rated that the expression of cathepsin D in HCC had prognostic value.

CONCLUSION: Chromogranin A and cathepsin D are expressed in a high proportion of HCC and the existence of cathepsin D in HCC might be related to processing of CgA. This is clearly a subject for further studies because of its potential clinical applications.

Key Words: carcinoma, hepatocellular/pathology, cathepsin D/metabolism, chromogranins/metabolism, microscopy, confocal



INTRODUCTION

The chromogranin A/secretogranin (CgA/Sg) acidic glycoprotein are widely distributed in vertebrate species. It has recently been proposed that CgA, a 50-kilodalton acidic glycoprotein, is costored and cosecreted with hormones and neurotransmitters in a variety of tissues. They thought to play a role in hormone packaging within secretory granules, in hormone secretion, and serve as prohormones for various proteolytic cleavage products[1]. CgA can be processed to several biologically active peptides such as pancreastatin. The single copy human CgA gene was isolated from a human fetal liver gene library[2]. The presence of CgA in hepatocellular carcinoma (HCC) was reported by Roskams et al[3]. They found that occasional positive cells or clusters of weakly CgA immunopositive cells were present in HCC. Cathepsin D is a lysosomal aspartyl proteinase[4], initially detected in breast cancer cell lines[5], which is widely distributed in normal tissues. The proteinase cathepsin D might be related to tumor invasion and metastasis through various mechanisms associated with its proteolytic activity. It was shown to degrade in vitro extracellular matrix and activate latent precursor forms of other proteinase involved in such processes[6]. Experimental studies have already demonstrated that invasion of HCC cells can be abrogated by proteinase inhibitors. Growing evidence indicates that lysosomal cathepsin D may promote carcinogenesis and tumor progression. The metastatic activity of cathepsin D injected into athymic mice was significantly higher than that of control groups. These results show that overexpression of cathepsin D increased the transformed phenotype of malignant cells in vitro and their metastatic potency in vivo[7]. Higher cathepsin D serum mass concentrations were found in HCC group as compared to control patients[8]. Plasma and ascitic fluid of rats bearing the Yoshida ascites hepatoma AH-130 were shown to contain high levels of proteolytic enzymes belonging to different classes active at neutral and acidic pH. Compared with those measured in control rat plasma, and tumor-bearing animals, the activity levels of lysosomal cathepsin D activity was about 5-fold higher in both plasma and ascitic fluid[9]. The expression of cathepsin D was significant predictors of the prognosis[10]. The role of cathepsin D has been studied in human breast cancer progression[6-8], but the results were highly variable and no agreement has yet been reached on its effects on clinical behaviour and prognosis. There has been no report available on the role of cathepsin D expression in the progression of human HCC. To analyse this, the double immunofluorescence staining techniques combined with laser scanning confocal microscopy (LSCM) were used to investigate CgA and cathepsin D expression in HCC patients.

MATERIALS AND METHODS
Patients

The study group comprised 85 patients with HCC diagnosed in 117 Hospital and Xijing Hospital of the Fourth Military Medical University from 1984 to 1997. The mean age of the patients was 51.4 ± 2.5 years (range 25-77 years). The female/male ratio was 28/57. The cohort was not entirely consecutive, since adequate tumor biopsy specimens for immunohistochemistry were not available in all cases.

Histological methods

The histological samples were surgically obtained biopsy specimens from the tumors which were fixed in buffered formalin (pH7.0), embedded in paraffin, sectioned at 5 or 10 micrometer, and stained with haematoxylin and eosin. The samples were graded histologically into 1 (well differentiated, 4 cases), 2 (moderately differentiated, 53 cases), 3 (poorly differentiated, 26 cases), 4 (undifferentisted type, 2 cases) categories as described in detail before according to the Edmondson-Steiner’s criteria[11].

Immunohistochemistry

Five- or ten-micrometer sections from the primary HCC were employed in the fluorescent immunohistochemical analysis of cathepsin D protein, using rabbit anti-human cathepsin D antibody (Dako, Glostrup, Denmark) diluted 1:300 in 10 mL/L bovine serum albumin (BSA)-phosphate-buffered saline (PBS). Several dilutions of the antibody were tested to find the optimal staining concentration, before the entire series was processed. The staining procedure was carried out as our previous reports[12], without protease treatment. Briefly, the steps included: ① the sections deparaffinized in xylene, hydrated in ethanol, and washed in 0.01 mol/L PBS, then pretreated with 30 mL/L normal goat serum for 40 min and rinsed in 0.1 mol/L PBS; ② incubation for 1 h in a 1:1000 dilution of the primary monoclonal a ntibody of CgA and in a 1:300 dilution of rabbit anti-human cathepsin D antibody in 10 mL/L BSA-PBS; ③ simultaneous incubation with 1:50 diluted secondary antibodies (biotin-conjugated goat anti-rabbit IgG and FITC-conjugated goat anti-mouse IgG) in 10 mL/L BSA-PBS. All secondary antibodies were obtained from SABC (Luoyang, PRC); ④ incubation with 1:2000 diluted Texas-red-conjugated streptavidin (Sigma) for 30 min. The sections were washed three times for 10 min after incubation steps 2 to 4, respectively, and were finally mounted in 50 g/L glycerin. The sections were examined with Bio-Rad 1024 LSCM. The specimens were excited with a laser beam at wavelengths of 568 nm (Texas Red) and 488 nm (FITC) and the emission light was focused through a pinhole aperture. The full field of view was scanned in square image formats of 512 × 512 pixels.

Scoring of CgA and cathepsin D protein expression

Firstly, the intensity of cytoplasmic fluorescence of the cancer cells in the entire section was scored into three categories. Cells showing no fluorescence for cathepsin D and CgA were considered as negative, cells with weak granular fluorescence (Figure 1) in the cytoplasm were scored as weak expressors, and cells with distinct cytoplasmic positivity (Figure 2) were scored as strong ones. Secondly, the fraction of cells in each of the staining categories in the entire section was also estimated in the areas with well-preserved tissue morphology. Areas with necrosis, or with distorted architecture, were excluded from the analysis. Thirdly, the presence in the invasion front of a distinct cathepsin D-positive cell zone composed of macrophage-like cells was scored positive or negative (determined in 65 cases). A breast cancer specimen showing intense uniform positivity for cathepsin D protein was used as a positive and negative control, with the expected results in all experiments. Since negative and weak positive showed no association with other prognostic parameters, the cases were grouped into positive (strongly stained cells) or negative (negative or weakly positive cells only) for further analysis.

Figure 1
Figure 1 Distribution of cathepsin D in HCC (grade 3). The positive reactivity was granular in cytoplasm (red). TR-labelled × 400
Figure 2
Figure 2 Localization of CgA in HCC (grade 3). The positive reactivity was homogeneous in cytoplasm (green). The positive cells distributed in patch pattern. FITC-labelled × 400
Controls

Primary antibodies were substituted by irrelevant antibodies and normal rabbit or goat serum as specific antibody control. PBS substituted for primary antibody as negative control. Primary antibody was omitted as blank control.

Statistical analysis

The Chi-square test was used in this study.

RESULTS
Relationship between expression of cathepsin D and histological features of HCC

Normal hepatocytes adjacent to carcinomas (n = 3) showed weak granular positivity for cathepsin D in the cytoplasm. Strong expression of cathepsin D in cancer cells was related to histopathological features (Table 1). Cells showing strong positivity for cathepsin D were present in 71/85 (83.5%) cases and were more common in grade 3-4 (26/28, 92.9%) and grade 2 (46/53, 86.8%) tumors than in grade 1 tumors (1/4, 25.0%, P < 0.01, Table 1). The positive reactivity was either granular or homogeneous in the cytoplasm (Figure 1). The positive cells distributed in disperse or patch pattern (Figure 1, Figure 3, Figure 4).

Table 1 Relationship between expression of cathepsin D and histologi cal features of HCC.
Histologic gradeExpression of cathepsin D
Positive (%)Negative (%)
11/4 (25.0)3/4 (75.0)
246/53 (86.8)a7/53 (13.2)
3 + 426/28 (92.9)b2/28 (7.1)
Figure 3
Figure 3 Coexpression of cathepsin D and CgA in HCC (grade 4). The positive cells distributed in disperse (yellow). TR-labelled cathepsin D, FITC-labelled CgA × 200
Figure 4
Figure 4 Coexpression of cathepsin D and CgA in HCC (grade 3). The positive cells distributed in disperse (yellow). TR-labelled cathepsin D, FITC-labelled CgA × 400
Relationship between expression of cathepsin D and patients’age

We found no significant correlation between age and cathepsin D expression. The mean age of patients with positive cathepsin D reaction was 52.1 ± 2.8 years (range 32-68 years) and 51.3 ± 4.5 years (range 28-71 years, P > 0.05) in the group with negative reaction.

Relationship between expression of CgA and histological grade of HCC

The CgA positive rate was 75.0% (3/4) in grade 1, 71.7% (38/53) in grade 2, and 71.4% (20/28) in grade 3-4 tumors (Table 2). No obvious relationship was observed between expression of CgA in cancer cells and the histopathological grades of HCC (P > 0.05). The positive reactivity was homogeneous in the cytoplasm (Figure 2, Figure 4, Figure 5).

Table 2 Relationship between expression of CgA and histologic grade of HCC.
Histologic gradeExpression of CgA
Positive (%)Negative (%)
13/4 (75.0)1/4 (25.0)
238/53 (71.7)a17/53 (28.3)
3 + 420/28 (71.4)b8/28 (28.6)
Figure 5
Figure 5 Expression of CgA in HCC (grade 3). The positive cells distributed in disperse or patch pattern (green). FITC-labelled × 200
Correlation of expression of cathepsin D and CgA in HCC

Coexpression of cathepsin D and CgA was found in most of HCC (56/85, Table 3, Figure 3, Figure 4, Figure 6). It accounted for 91.8% of CgA-positive cases, and 78.9% (56/71) of cathepsin D-positive ones. Colocalization of cathepsin D and CgA was yellow observed by LSCM (Figure 3, Figure 4, Figure 6).

Table 3 Relationship between expression of cathepsin D and CgA in HCC.
Expression of CgAnExpression of cathepsin D
PositiveNegative
Positive61565
Negative24159
Total857114
Figure 6
Figure 6 Coexpression of cathepsin D and CgA in HCC (grade 2). The positive cells distributed in patch pattern (yellow). TR-labelled cathepsin D, FITC-labelled CgA × 400
DISCUSSION

CgA is the major member of the granin family of acidic secretory glycoproteins that are expressed in all endocrine and neuroendocrine cells. Granins have been proposed to play multiple roles in the secretory process. Intracellularly, granins play a role in targeting peptide hormones and neurotransmitters to granules of the regulated pathway by virtue of their ability to aggregate in the low-pH, high-calcium environment of the trans-Golgi network. Extracellularly, peptides formed as a result of proteolytic processing of granins regulate hormone secretion. Some conserved features of the mature CgA protein are polyglutamic acids, calcium-binding sites, and several pairs of basic amino acids. The first two features are important for its intracellular functions, and the latter characteristic suggested that peptides could be released from the molecule by precursor processing enzymes. Several biologically active peptides encoded within the CgA molecule, such as vasostatin, beta-granin, chromostatin, pancreastatin, and parastatin act predominantly to inhibit hormone and neurotran smitter release in an autocrine or paracrine fashion. The biosynthesis of CgA is regulated by many different factors, including steroid hormones and agents that act through a variety of signalling pathways. CgA biosynthesis and that of the resident hormone or neurotransmitter can be regulated differentially. The widesp read distribution of CgA has made the measurement of circulating immunoreactive CgA a valuable tool in the diagnosis of neuroendocrine neoplasia, and CgA immuno histochemistry can help identify the neuroendocrine nature of tumors. Recent molecular biological studies are identifying those elements in the CgA gene promoter responsible for its specific neuroendocrine cell expression.

Cathepsin D was purified to apparently homogeneous form from normal human liver and hepatoma. The puried enzyme could not be distinguished between normal liver and hepatoma in terms of specific activity, subunit composition, antigenicity, amino acid composition and tryptic peptides. However, the hepatom a enzyme was treated with endo-beta-N-acetylglucosaminidase H, the acidic variant forms disappeared and were converted into forms identical to those of normal liver. The content of mannose-6-phosphate in the hepatoma enzyme was twice as much as that in the normal liver enzyme. Thus, charge heterogeneity found in hepatoma cathepsin D is ascribed to increased phosphorylation on oligosaccharides bound to the enzyme, most probably due to cancer-associated, impaired processing in carbohydrate moiety. A significant elevation of cathepsin D activity per tissue proteins was observed in hepatoma as compared to normal liver. In contrast, true specific activity per cathepsin D protein in hepatoma was significantly lower than that of normal liver. The lower true specific activity in hepatoma tissue may be attributed to an increased content in an inactive, large-molecular precursor form of the enzyme[13].

Cathepsin D is encoded by a gene located on chromosome 11p15, but its increased expression is not usually due to gene rearrangement or amplification[14]. Instead, it can be induced by estrogens or several other factors in the cellular micro-environment[15,16]. Cathepsin D exists in the cell as a precursor for procathepsin D. In the normal hepatocytes, most of the procathepsin D is changed to an active form in the lysosomes, while in HCC cells the processing of procathepsin D is disturbed. Procathepsin D is accumulated in the cells, since smaller fraction is secreted than in normal liver tissues[17]. Procathepsin D has proteolytic activity and autocrine mitogenic effect[18], both of which suggest some functions in invasion and metastasis. Cathepsin D is a physiological regulator of other cathepsins (B and L) by activating their precusors[19], or possibly by inactivating endogenous inhibitors of cathepsins[20]. Cathepsin D was usually expressed in normal hepatocytes, while in malighant tumors the fluorescent staining showed regional variation and the fraction of strongly stained cells increased as the tumors became less differentiated and usually clinically more malignant. In HCC, increased expression was related to a high grade. The situation was also found in breast carcinomas[21]. However, the dissemination of the tumor to lymph nodes and to distant sites suggested a relationship between invasive potential and the expression of cathepsin D. Strong expression of cathepsin D was associated with cell proliferation and expression of growth factor receptors[22]. Our previous studies also proved that the hepatoma cells expressed epithelium growth factor and its receptors[22] and CgA[23]. Thus, it is likely that the strong expression of cathepsin D is due to induction of cathepsin D synthesis by epithelium growth factor. The higher proliferation rate of strongly cathepsin D-positive tumors may be partly related to a mitogenic effect of cathepsin D[18,24]. These findings, together with the clinical observations that a positive correlation between levels of expression of cathepsin D activity and malignant progression of some human neoplasms, seem to support this hypothesis[25].

The prognostic value of cathepsin D expression in neoplasms is a matter of controversy and the results of this study suggest that the expression of cathepsin D in HCC cells has prognostic value over already established prognostic factors.

In conclusion, cathepsin D is expressed in a high proportion of HCC. This is clearly a subject for further studies because of its potential clinical applications. Chromogenic peptides act as substrates for cathepsins[26], so the higher expression of cathepsin D, the lower expression of CgA in HCC and vice versa.

Footnotes

Edited by MA JY

References
1.  Lloyd RV, Hawkins K, Jin L, Kulig E, Fields K. Chromogranin A, chromogranin B and secretogranin II mRNAs in the pituitary and adrenal glands of various mammals. Regulation of chromogranin A, chromogranin B and secretogranin II mRNA levels by estrogen. Lab Invest. 1992;67:394-404.  [PubMed]  [DOI]  [Cited in This Article: ]
2.  Mouland AJ, Bevan S, White JH, Hendy GN. Human chromogranin A gene. Molecular cloning, structural analysis, and neuroendocrine cell-specific expression. J Biol Chem. 1994;269:6918-6926.  [PubMed]  [DOI]  [Cited in This Article: ]
3.  Roskams T, Willems M, Campos RV, Drucker DJ, Yap SH, Desmet VJ. Parathyroid hormone-related peptide expression in primary and metastatic liver tumours. Histopathology. 1993;23:519-525.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 42]  [Cited by in F6Publishing: 44]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
4.  Morisset M, Capony F, Rochefort H. The 52-kDa estrogen-induced protein secreted by MCF7 cells is a lysosomal acidic protease. Biochem Biophys Res Commun. 1986;138:102-109.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 70]  [Cited by in F6Publishing: 80]  [Article Influence: 2.1]  [Reference Citation Analysis (0)]
5.  Westley B, Rochefort H. A secreted glycoprotein induced by estrogen in human breast cancer cell lines. Cell. 1980;20:353-362.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 350]  [Cited by in F6Publishing: 377]  [Article Influence: 8.6]  [Reference Citation Analysis (0)]
6.  Liotta LA. Tumor invasion and metastases: role of the basement membrane. Warner-Lambert Parke-Davis Award lecture. Am J Pathol. 1984;117:339-348.  [PubMed]  [DOI]  [Cited in This Article: ]
7.  Garcia M, Derocq D, Pujol P, Rochefort H. Overexpression of transfected cathepsin D in transformed cells increases their malignant phenotype and metastatic potency. Oncogene. 1990;5:1809-1814.  [PubMed]  [DOI]  [Cited in This Article: ]
8.  Leto G, Tumminello FM, Pizzolanti G, Montalto G, Soresi M, Ruggeri I, Gebbia N. Cathepsin D serum mass concentrations in patients with hepatocellular carcinoma and/or liver cirrhosis. Eur J Clin Chem Clin Biochem. 1996;34:555-560.  [PubMed]  [DOI]  [Cited in This Article: ]
9.  Isidoro C, Démoz M, De Stefanis D, Baccino FM, Bonelli G. High levels of proteolytic enzymes in the ascitic fluid and plasma of rats bearing the Yoshida AH-130 hepatoma. Invasion Metastasis. 1995;15:116-124.  [PubMed]  [DOI]  [Cited in This Article: ]
10.  Isola J, Weitz S, Visakorpi T, Holli K, Shea R, Khabbaz N, Kallioniemi OP. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol. 1993;11:36-43.  [PubMed]  [DOI]  [Cited in This Article: ]
11.  Edmondson HA, STEINER PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer. 1954;7:462-503.  [PubMed]  [DOI]  [Cited in This Article: ]
12.  Wang CM, Huang XF, Pan BR, Dai XW, Ma FC, Zhao YM. Expression of chromogranin C/secretogranin II and pancreastatin in the pancre-atic ductal carcinoma. Huaren Xiaohua Zazhi. 1998;6:470-473.  [PubMed]  [DOI]  [Cited in This Article: ]
13.  Maguchi S. [Tumor-associated impairment of the processing of hepatoma cathepsin D]. Hokkaido Igaku Zasshi. 1988;63:23-35.  [PubMed]  [DOI]  [Cited in This Article: ]
14.  Augereau P, Garcia M, Mattei MG, Cavailles V, Depadova F, Derocq D, Capony F, Ferrara P, Rochefort H. Cloning and sequencing of the 52K cathepsin D complementary deoxyribonucleic acid of MCF7 breast cancer cells and mapping on chromosome 11. Mol Endocrinol. 1988;2:186-192.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 66]  [Cited by in F6Publishing: 70]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
15.  Rio MC, Bellocq JP, Daniel JY, Tomasetto C, Lathe R, Chenard MP, Batzenschlager A, Chambon P. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science. 1988;241:705-708.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 246]  [Cited by in F6Publishing: 268]  [Article Influence: 7.4]  [Reference Citation Analysis (0)]
16.  Rochefort H, Cavailles V, Augereau P, Capony F, Maudelonde T, Touitou I, Garcia M. Overexpression and hormonal regulation of pro-cathepsin D in mammary and endometrial cancer. J Steroid Biochem. 1989;34:177-182.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 60]  [Cited by in F6Publishing: 65]  [Article Influence: 1.9]  [Reference Citation Analysis (0)]
17.  Rijnboutt S, Kal AJ, Geuze HJ, Aerts H, Strous GJ. Mannose 6-phosphate-independent targeting of cathepsin D to lysosomes in HepG2 cells. J Biol Chem. 1991;266:23586-23592.  [PubMed]  [DOI]  [Cited in This Article: ]
18.  Rochefort H, Capony F, Garcia M, Cavaillès V, Freiss G, Chambon M, Morisset M, Vignon F. Estrogen-induced lysosomal proteases secreted by breast cancer cells: a role in carcinogenesis? J Cell Biochem. 1987;35:17-29.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 146]  [Cited by in F6Publishing: 161]  [Article Influence: 4.4]  [Reference Citation Analysis (0)]
19.  Kane SE, Gottesman MM. The role of cathepsin L in malignant transformation. Semin Cancer Biol. 1990;1:127-136.  [PubMed]  [DOI]  [Cited in This Article: ]
20.  Okamoto H, Greenbaum LM. Kininogen substrates for trypsin and cathepsin D in human, rabbit and rat plasmas. Life Sci. 1983;32:2007-2013.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 79]  [Cited by in F6Publishing: 58]  [Article Influence: 1.4]  [Reference Citation Analysis (0)]
21.  Charpin C, Devictor B, Bonnier P, Andrac L, Lavaut MN, Allasia C, Piana L. Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors. J Pathol. 1993;170:463-470.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 16]  [Cited by in F6Publishing: 21]  [Article Influence: 0.7]  [Reference Citation Analysis (0)]
22.  Huang XF, Zhang YQ, Bu YA, Wu MH. Immunocytochemical localization of epidermal growth factor and its receptor on the rat hepatoma cells. Chin Sci Bulletin. 1996;41:1543-1546.  [PubMed]  [DOI]  [Cited in This Article: ]
23.  Wang CM, Huang XF, Zhang YQ, Liu YF, Zhao YL, Su Q. Expression of cytokeratin and chromogranin A in the rat hepatoma cell line: studied with laser scaning confocal microscopy. J Cell Mol Immunol. 1998;13:35-36.  [PubMed]  [DOI]  [Cited in This Article: ]
24.  Vignon F, Capony F, Chambon M, Freiss G, Garcia M, Rochefort H. Autocrine growth stimulation of the MCF 7 breast cancer cells by the estrogen-regulated 52 K protein. Endocrinology. 1986;118:1537-1545.  [PubMed]  [DOI]  [Cited in This Article: ]  [Cited by in Crossref: 225]  [Cited by in F6Publishing: 209]  [Article Influence: 5.5]  [Reference Citation Analysis (0)]
25.  Leto G, Gebbia N, Rausa L, Tumminello FM. Cathepsin D in the malignant progression of neoplastic diseases (review). Anticancer Res. 1992;12:235-240.  [PubMed]  [DOI]  [Cited in This Article: ]
26.  Bonelli G, Kay J, Tessitore L, Jupp RA, Isidoro C, Norey CG, Autelli R, Richards AD, Baccino FM. Purification and properties of cathepsin D from rat Yoshida ascites hepatoma AH-130. Biol Chem Hoppe Seyler. 1988;369 Suppl:323-327.  [PubMed]  [DOI]  [Cited in This Article: ]